Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-25 of 53 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3

Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs.
Zhang D, Ma B, Dragovich PS, Ma L, Chen S, Chen EC, Ye X, Liu J, Pizzano J, Bortolon E, Chan E, Zhang X, Chen YC, Levy ES, Yauch RL, Khojasteh SC, Hop CECA
Commun Med (Lond), 4(1):87, 16 May 2024
Cited by: 0 articles | PMID: 38755248 | PMCID: PMC11099041
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Androgen receptor-negative prostate cancer is vulnerable to SWI/SNF-targeting degrader molecules
Thienger P, Rubin PD, Yao X, Benjak A, Shah SR, Leung AK, de Brot S, Naveed A, Shi M, Tremblay J, Triscott J, Cassanmagnago G, Bolis M, Mela L, Beltran H, Chen Y, Piscuoglio S, Yu H, Ng CKY, [...] Rubin MA
bioRxiv, 27 Mar 2024
Cited by: 0 articles | PPR: PPR828200
Add to export list Preprint
Smarca2 genetic ablation is phenotypically benign in a safety assessment of tamoxifen-inducible conditional knockout rats.
Maher J, Stagg N, Cain G, Andaya R, Katavolos P, Gallardo-Chang F, Pham A, Ye X, Januario T, Alcantar T, Caothien R, Roose-Girma M, Zhang D, Li R, Chen S, Yauch RL
Toxicol Appl Pharmacol, 475:116627, 14 Jul 2023
Cited by: 1 article | PMID: 37453479
Add to export list
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
Cantley J, Ye X, Rousseau E, Januario T, Hamman BD, Rose CM, Cheung TK, Hinkle T, Soto L, Quinn C, Harbin A, Bortolon E, Chen X, Haskell R, Lin E, Yu SF, Del Rosario G, Chan E, Dunlap D, [...] Yauch RL
Nat Commun, 13(1):6814, 10 Nov 2022
Cited by: 24 articles | PMID: 36357397 | PMCID: PMC9649729
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients.
Fernando TM, Piskol R, Bainer R, Sokol ES, Trabucco SE, Zhang Q, Trinh H, Maund S, Kschonsak M, Chaudhuri S, Modrusan Z, Januario T, Yauch RL
Nat Commun, 11(1):5551, 03 Nov 2020
Cited by: 44 articles | PMID: 33144586 | PMCID: PMC7609548
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types.
Wagle MC, Kirouac D, Klijn C, Liu B, Mahajan S, Junttila M, Moffat J, Merchant M, Huw L, Wongchenko M, Okrah K, Srinivasan S, Mounir Z, Sumiyoshi T, Haverty PM, Yauch RL, Yan Y, Kabbarah O, Hampton G, [...] Huang SA
NPJ Precis Oncol, 2(1):7, 07 Mar 2018
Cited by: 86 articles | PMID: 29872725 | PMCID: PMC5871852
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T, Ye X, Bainer R, Alicke B, Smith T, Haley B, Modrusan Z, Gould S, Yauch RL
Proc Natl Acad Sci U S A, 114(46):12249-12254, 30 Oct 2017
Cited by: 41 articles | PMID: 29087303 | PMCID: PMC5699030
Add to export list Free full text in Europe PMC
Reproducible pharmacogenomic profiling of cancer cell line panels.
Haverty PM, Lin E, Tan J, Yu Y, Lam B, Lianoglou S, Neve RM, Martin S, Settleman J, Yauch RL, Bourgon R
Nature, 533(7603):333-337, 01 May 2016
Cited by: 161 articles | PMID: 27193678
Add to export list
Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function.
Storm EE, Durinck S, de Sousa e Melo F, Tremayne J, Kljavin N, Tan C, Ye X, Chiu C, Pham T, Hongo JA, Bainbridge T, Firestein R, Blackwood E, Metcalfe C, Stawiski EW, Yauch RL, Wu Y, de Sauvage FJ
Nature, 529(7584):97-100, 23 Dec 2015
Cited by: 146 articles | PMID: 26700806
Add to export list
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.
Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, Tsui V, Durham AB, Dlugosz AA, Haverty PM, Bourgon R, Tang JY, Sarin KY, Dirix L, Fisher DC, Rudin CM, Sofen H, Migden MR, Yauch RL, de Sauvage FJ
Cancer Cell, 27(3):327-341, 01 Mar 2015
Cited by: 218 articles | PMID: 25759019 | PMCID: PMC5675004
Add to export list Free full text in Europe PMC
A comprehensive transcriptional portrait of human cancer cell lines.
Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang Z, Liu H, Degenhardt J, Mayba O, Gnad F, Liu J, Pau G, Reeder J, Cao Y, Mukhyala K, Selvaraj SK, Yu M, Zynda GJ, Brauer MJ, Wu TD, [...] Zhang Z
Nat Biotechnol, 33(3):306-312, 08 Dec 2014
Cited by: 396 articles | PMID: 25485619
Add to export list
AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs.
Wilson C, Ye X, Pham T, Lin E, Chan S, McNamara E, Neve RM, Belmont L, Koeppen H, Yauch RL, Ashkenazi A, Settleman J
Cancer Res, 74(20):5878-5890, 14 Aug 2014
Cited by: 88 articles | PMID: 25125659
Add to export list
Discovery and preclinical development of vismodegib.
Gould SE, Low JA, Marsters JC, Robarge K, Rubin LL, de Sauvage FJ, Sutherlin DP, Wong H, Yauch RL
Expert Opin Drug Discov, 9(8):969-984, 23 May 2014
Cited by: 28 articles | PMID: 24857041
Add to export list Review
Discovery and development of DNA methylation-based biomarkers for lung cancer.
Walter K, Holcomb T, Januario T, Yauch RL, Du P, Bourgon R, Seshagiri S, Amler LC, Hampton GM, S Shames D
Epigenomics, 6(1):59-72, 01 Feb 2014
Cited by: 17 articles | PMID: 24579947
Add to export list
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.
Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, Raja R, Mohan S, Patel R, Desai R, Fu L, Do A, Parab V, Xia X, Januario T, Louie SG, Filvaroff E, Shames DS, Wistuba I, [...] Yauch RL
Clin Cancer Res, 20(17):4488-4498, 31 Mar 2014
Cited by: 79 articles | PMID: 24687921 | PMCID: PMC4504679
Add to export list Free full text in Europe PMC
Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors.
Shames DS, Elkins K, Walter K, Holcomb T, Du P, Mohl D, Xiao Y, Pham T, Haverty PM, Liederer B, Liang X, Yauch RL, O'Brien T, Bourgon R, Koeppen H, Belmont LD
Clin Cancer Res, 19(24):6912-6923, 04 Oct 2013
Cited by: 51 articles | PMID: 24097869
Add to export list
Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
Koeppen H, Rost S, Yauch RL
J Pathol, 232(2):210-218, 01 Jan 2014
Cited by: 25 articles | PMID: 24105670
Add to export list Review
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC
J Clin Oncol, 31(32):4105-4114, 07 Oct 2013
Cited by: 304 articles | PMID: 24101053 | PMCID: PMC4878106
Add to export list Free full text in Europe PMC
High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck.
Shames DS, Carbon J, Walter K, Jubb AM, Kozlowski C, Januario T, Do A, Fu L, Xiao Y, Raja R, Jiang B, Malekafzali A, Stern H, Settleman J, Wilson TR, Hampton GM, Yauch RL, Pirzkall A, Amler LC
PLoS One, 8(2):e56765, 28 Feb 2013
Cited by: 40 articles | PMID: 23468880 | PMCID: PMC3586092
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL, Low JA
Clin Cancer Res, 19(1):258-267, 18 Oct 2012
Cited by: 117 articles | PMID: 23082002
Add to export list
HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.
Penuel E, Li C, Parab V, Burton L, Cowan KJ, Merchant M, Yauch RL, Patel P, Peterson A, Hampton GM, Lackner MR, Hegde PS
Mol Cancer Ther, 12(6):1122-1130, 27 Mar 2013
Cited by: 15 articles | PMID: 23536720
Add to export list
Noncovalent wild-type-sparing inhibitors of EGFR T790M.
Lee HJ, Schaefer G, Heffron TP, Shao L, Ye X, Sideris S, Malek S, Chan E, Merchant M, La H, Ubhayakar S, Yauch RL, Pirazzoli V, Politi K, Settleman J
Cancer Discov, 3(2):168-181, 10 Dec 2012
Cited by: 49 articles | PMID: 23229345 | PMCID: PMC3576842
Add to export list Free full text in Europe PMC
A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.
Kaye SB, Fehrenbacher L, Holloway R, Amit A, Karlan B, Slomovitz B, Sabbatini P, Fu L, Yauch RL, Chang I, Reddy JC
Clin Cancer Res, 18(23):6509-6518, 02 Oct 2012
Cited by: 77 articles | PMID: 23032746
Add to export list
Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, Epstein EH
N Engl J Med, 366(23):2180-2188, 01 Jun 2012
Cited by: 305 articles | PMID: 22670904 | PMCID: PMC4362529
Add to export list Free full text in Europe PMC
DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer.
Walter K, Holcomb T, Januario T, Du P, Evangelista M, Kartha N, Iniguez L, Soriano R, Huw L, Stern H, Modrusan Z, Seshagiri S, Hampton GM, Amler LC, Bourgon R, Yauch RL, Shames DS
Clin Cancer Res, 18(8):2360-2373, 19 Jan 2012
Cited by: 59 articles | PMID: 22261801
Add to export list

1-25 of 53 results

1 2 3

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

Partnerships & funding